**Penn Startups Raising Capital**

**Connected Health and Digital Health Companies**

- **Cogwear** (series A) provides clinical-grade insights into brain health, peace, and performance. Powered by nanotechnology sensors, machine learning, and breakthrough science, Cogwear’s wearable technology enables physiological brain measurement and ongoing assessment for better care, lower costs, and extended lives.
- **Galileo** (seed) is developing decision support tools for medical professionals assessing medical images.
- **Neuralert Technologies** (series A) offers non-invasive, wrist-worn medical devices to automatically detect and alert clinicians to the onset of stroke. Neuralert’s proprietary algorithm analyzes arm asymmetry data, a key indicator of stroke, to enable faster stroke detection and enhance care delivery, thereby decreasing costs and reducing incidence of disability.
- **Vasowatch** (pre-seed) is developing a wearable medical device to predict the risk of postpartum hemorrhage, enhancing childbirth safety. Vasowatch has secured an exclusive technology option and advanced a groundbreaking wearable technology with up to 10x greater predictive accuracy for postpartum hemorrhage.
- **Quantaras** (seed) offers advanced body-wide quantification of medical images for applications in radiology, radiation oncology, and medical oncology. Its unique Automatic Anatomy Recognition software supports recognition and delineation of anatomical objects and diseased tissue in multiple body regions in MRI, CT, and PET/CT images. Formerly QRS.

**Diagnostic Companies**

- **ACE Genomics** (seed) is developing enzymes to assess epigenetic modifications to allow for advanced research tools and diagnostics.
- **FloBio** (seed) is a precision diagnostics company focused on rapidly measuring blood function and bleeding risk to reduce preventable complications. FloBio’s first product provides actionable information to clinicians to safely manage the treatment of at-risk patients on modern blood thinners (Direct Oral Anticoagulants), where no FDA-approved test is available.
- **Instanosis** (seed) focuses on commercialization of an innovative and broadly-applicable point-of-care platform to detect ultra-low concentrations of disease biomarkers, with the lead application being an ultrasensitive and low-cost COVID antigen test.
- **Vellum Biosciences** (seed) is designing non-invasive imaging tools that can effectively monitor the kinetic profiles, biodistribution, and trafficking patterns of cell and gene therapies in patients.
- **Brainstorm Diagnostics** (seed) is developing blood biomarker technology for the early diagnosis of traumatic brain injury.

**Advanced Materials Companies**

- **Enachip** (series A) is developing and commercializing a disruptive technology platform compatible with existing semiconductor manufacturing. Their innovative materials and manufacturing process for power management components, that exist in every electronic device, enables up to 70% solution size reduction, up to 30% efficiency increase, and up to 3X cost reduction.
- **Hydropore** (seed) is developing a new approach for producing Hydrogen in a cost effective and sustainable process.

**If you are interested in connecting about these startups, please email Laurie Actman (lactman@upenn.edu).**
Penn Startups Raising Capital

**Therapeutic Companies**

- **Cantius Therapeutics** (seed) has a unique and well-placed strategy to treat cachexia and block nausea/emesis. GRASP technology utilizes small peptides that penetrate the brainstem to antagonize the GFRAL-Ret receptor complex. This receptor complex, expressed exclusively in the brainstem, was recently established as the sole mediator of GDF15 (MIC-1) signaling, a cytokine critical in disease-induced cachexia, anorexia, and emetic behaviors from cancer, chemotherapy, and pregnancy-induced morning sickness.

- **EpiVario** (series A) is a preclinical stage biotechnology company that is developing neuroepigenetic modulators to treat memory related psychiatric disorders. Our newly discovered epigenetic regulatory mechanism, ACSS2, provides a target for treating memory-related neuropsychiatric disorders. Based on this paradigm-shifting finding, EpiVario is developing pharmacotherapeutics to treat anxiety and addiction disorders, including PTSD and alcohol use disorder.

- **Intervir** (seed) (series A) is a pre-clinical stage biotechnology company with an experienced drug discovery team that is focused on first in-class antiviral therapeutics. Intervir’s novel, host-oriented mechanism of action disrupts budding, release and dissemination of viruses. Target indications are deadly hemorrhagic viruses and emerging and mutating viruses such as SARS-CoV2. The company is seeking funding of $7 million to advance through a phase I trial.

- **Linnaeus Therapeutics** (series C) is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapies.

- **Mechano Therapeutics** (seed) is developing a drug-delivery platform for enhanced delivery of therapeutics to musculoskeletal tissues. The company’s microcapsule technology leverages the natural mechanical forces of the joint to activate drug release in a targeted and controlled manner.

- **PhyloPharma** (series A) is developing a novel plant-based technology platform for cost-effective and shelf-stable protein delivery.

- **Trevax LLC** (seed) is developing a PARP inhibitor theragnostic platform to treat cancers. The combination of molecular imaging and radionuclide therapy is designed to precisely target specific tumor tissue.

**If you are interested in connecting about these startups, please email Laurie Actman (lactman@upenn.edu).**

**Medical Device Companies**

- **Verismo Therapeutics** (series A) is pioneering novel chimeric antigen receptor T-cells for cancer using CARs engineered to mimic the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T-cells and NK cells. This novel KIR-CAR design is anticipated to improve persistence and efficacy against the most aggressive solid tumors.

- **Vetigenics** (series A) is a clinical-stage biopharmaceutical company committed to improving the health of companion animals through the development of entirely species-specific, safe and effective antibody-based immunotherapies to treat their cancers and other chronic diseases.

- **AltruMed** (seed) is focused on medical technologies in the harm reduction space, developing an armband that detects an opioid overdose and automatically injects the antidote.

- **Neoneur** (seed) is focused on the monitoring and assessment of neonate and infant feeding development, a key development parameter.

- **Ostiiio** (seed) offers a novel approach to correct craniofacial deformities and deficiencies utilizing a fully implantable, magnetically-driven, bony distraction device.

- **Ventru** (seed) is developing neurosurgical innovations that improve safety and accessibility. Its novel Device for Intraventricular Entry (DIVE) is a stereotactic guide that assists surgeons with the safe placement of drains for patients suffering from hydrocephalus.

- **Cerespectus** (seed) is addressing a critical challenge in medical treatment delivery to the central nervous system by developing a catheter that incorporates real-time anatomic video feedback and fluoroscopic assistance. This innovative approach aims to provide precise gene therapy delivery, tackling the complex issue of treating disorders within the central nervous system.

- **RightAir** (seed plus) is a MedTech pioneer that has developed the only portable, wearable cuirass-style ventilator designed to reduce the work of breathing for patients struggling with respiratory disorders. The simple and easy to use device is intended to offload the work of breathing without limiting the user’s everyday activities, allowing patients to maintain or increase their physical activity and stay out of the hospital.